DK33190D0 - Hiv-3 retrovirus og anvendelse heraf - Google Patents

Hiv-3 retrovirus og anvendelse heraf

Info

Publication number
DK33190D0
DK33190D0 DK033190A DK33190A DK33190D0 DK 33190 D0 DK33190 D0 DK 33190D0 DK 033190 A DK033190 A DK 033190A DK 33190 A DK33190 A DK 33190A DK 33190 D0 DK33190 D0 DK 33190D0
Authority
DK
Denmark
Prior art keywords
hiv
retrovirus
nucleic acid
acid sequence
region
Prior art date
Application number
DK033190A
Other languages
English (en)
Other versions
DK33190A (da
DK176078B1 (da
Inventor
Robert De Leys
Bart Vanderborght
Eric Samen
Hugo Van Heuverswyn
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8199044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK33190(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of DK33190D0 publication Critical patent/DK33190D0/da
Publication of DK33190A publication Critical patent/DK33190A/da
Application granted granted Critical
Publication of DK176078B1 publication Critical patent/DK176078B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK199000331A 1988-06-09 1990-02-08 HIV-3 retrovirus og anvendelse heraf DK176078B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP88109200 1988-06-09
EP88109200A EP0345375B1 (en) 1988-06-09 1988-06-09 HIV-3 retrovirus and its use
EP8900643 1989-06-08
PCT/EP1989/000643 WO1989012094A1 (en) 1988-06-09 1989-06-08 Hiv-3 retrovirus and its use

Publications (3)

Publication Number Publication Date
DK33190D0 true DK33190D0 (da) 1990-02-08
DK33190A DK33190A (da) 1990-03-28
DK176078B1 DK176078B1 (da) 2006-04-10

Family

ID=8199044

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199000331A DK176078B1 (da) 1988-06-09 1990-02-08 HIV-3 retrovirus og anvendelse heraf

Country Status (10)

Country Link
US (7) US5304466A (da)
EP (3) EP0345375B1 (da)
JP (1) JP2882654B2 (da)
AT (1) ATE120234T1 (da)
AU (1) AU625970B2 (da)
CY (1) CY2051B1 (da)
DE (1) DE3853422T2 (da)
DK (1) DK176078B1 (da)
ES (1) ES2072853T3 (da)
WO (1) WO1989012094A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364933A (en) * 1986-03-03 1994-11-15 Institut Pasteur Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
EP0345375B1 (en) * 1988-06-09 1995-03-22 N.V. Innogenetics S.A. HIV-3 retrovirus and its use
ES2053014T5 (es) * 1990-06-15 2001-02-16 Innogenetics Nv El retrovirus sivcpz-ant y sus usos.
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
ES2287969T3 (es) * 1992-03-06 2007-12-16 Innogenetics N.V. Peptidos de vih.
EP0591914B2 (de) 1992-10-06 2010-02-10 Siemens Healthcare Diagnostics Products GmbH Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en) * 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
EP0787191B2 (fr) 1994-10-20 2011-10-26 Institut Pasteur Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
WO1996040763A2 (en) * 1995-06-07 1996-12-19 Abbott Laboratories Peptides for hiv-1 detection
US5612473A (en) * 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
ES2187947T5 (es) † 1997-03-10 2014-01-29 Roche Diagnostics Gmbh Procedimiento para la detección simultánea de antígenos de HIV y anticuerpos de HIV
US5922533A (en) * 1997-08-15 1999-07-13 Abbott Laboratories Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
US6846905B2 (en) 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
US7244570B2 (en) 1998-08-04 2007-07-17 Luminex Molecular Diagnostics, Inc. Methods and compositions for modulating “marginally indiscriminant” hybridizations
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
WO2001004361A2 (en) 1999-07-09 2001-01-18 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification
OA12156A (en) 1999-11-16 2006-05-08 Geneart Gmbh Geschellschaft Fu The genome of the HIV-1 inter-subtype (C/B') and use thereof.
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003098215A1 (en) * 2002-05-16 2003-11-27 Medmira Inc. Rapid vaccinia antibody detection device, method and test kit
US7786288B2 (en) * 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site
CN101969962B (zh) * 2007-10-22 2014-10-22 艾玛菲克有限公司 包含磷酸化氨基酸、合成的磷酸化肽和胃石蛋白的稳定的无定形碳酸钙
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (da) 2011-06-10 2018-05-22 Univ Oregon Health & Science Cmv-glycoproteiner og rekombinante vektorer
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CA2988068C (en) 2015-06-04 2024-01-09 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
WO2018078616A1 (en) 2016-10-25 2018-05-03 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia
KR20220038056A (ko) 2019-07-23 2022-03-25 아모피컬 리미티드 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217861A (en) * 1983-09-15 1993-06-08 Institut Pasteur Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor
DE3587512T2 (de) * 1984-10-18 1993-12-02 Centre Nat Rech Scient Hüllenantigene vom menschlichen Immunodefizienz-Virus und deren Verwendungen.
US5066782A (en) * 1986-01-22 1991-11-19 Institut Pasteur Retrovirus capable of causing AIDS, means and method for detecting it in vitro
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
EP0320495B1 (fr) * 1986-01-22 2000-08-02 Institut Pasteur Procédé de fabrication récombinante des protéines derivées de HIV-2 et culture cellulaire exprimant des protéines de HIV-2
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
SE8701765L (sv) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
EP0345375B1 (en) * 1988-06-09 1995-03-22 N.V. Innogenetics S.A. HIV-3 retrovirus and its use

Also Published As

Publication number Publication date
US6013484A (en) 2000-01-11
DK33190A (da) 1990-03-28
EP1369427A2 (en) 2003-12-10
EP0657532A1 (en) 1995-06-14
EP0345375B1 (en) 1995-03-22
AU625970B2 (en) 1992-07-23
EP0345375A1 (en) 1989-12-13
CY2051B1 (en) 1998-04-30
EP1369427A3 (en) 2004-05-12
EP0657532B1 (en) 2003-12-17
US6265200B1 (en) 2001-07-24
JPH02504583A (ja) 1990-12-27
US5858647A (en) 1999-01-12
US20030039954A1 (en) 2003-02-27
DK176078B1 (da) 2006-04-10
JP2882654B2 (ja) 1999-04-12
WO1989012094A1 (en) 1989-12-14
DE3853422D1 (de) 1995-04-27
ATE120234T1 (de) 1995-04-15
ES2072853T3 (es) 1995-08-01
AU3762889A (en) 1990-01-05
DE3853422T2 (de) 1995-10-26
US5567603A (en) 1996-10-22
US5795743A (en) 1998-08-18
US5304466A (en) 1994-04-19

Similar Documents

Publication Publication Date Title
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
Salminen et al. Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
DK605987D0 (da) Bestemte dna-sekvenser afledt af et papillomavirus-genom, deres anvendelse til in vitro diagnoseformaal og fremstilling af antigeniske praeparater
AU1225088A (en) Peptides having immunological properties 2-hiv-2
KR970701782A (ko) 생체내에서 유전자의 통합성 발현(Coordinate in vivo gene expression)
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
KR950032278A (ko) 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도
JP2001527029A5 (da)
DE60026199T2 (de) Synthetische Gene für gagpol und deren Verwendungen
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
US20070172930A1 (en) process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof
DK0946731T3 (da) Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser
Matthews et al. Prospects for development of a vaccine against HTLV-III-related disorders
KR900702045A (ko) 천연 hiv gp 160의 제조방법
US7713530B2 (en) HIV-1 subtype isolate regulatory/accessory genes, and modification and derivatives thereof
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
Chen et al. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses
Pal et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A
DK0592636T3 (da) Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi
Blancou et al. Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus
CA2408786A1 (en) Retroviral vectors comprising an enhanced 3' transcription termination structure

Legal Events

Date Code Title Description
PUP Patent expired